InflaRx (IFRX) Share-based Compensation (2017 - 2026)
InflaRx (IFRX) posted Share-based Compensation of $1.1 million for Q1 2026, up 263.7% sequentially from $302937.7 in Q4 2025, and down 57.76% YoY from $2.6 million in Q1 2025.
InflaRx (IFRX) Share-based Compensation (2017 - 2026) Analysis & Trends
InflaRx has reported Share-based Compensation for 10 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Share-based Compensation fell 57.76% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 32.8% YoY) and the FY2025 annual result came in at $5.0 million, up 14.11% from the prior year.
- Share-based Compensation rose to $1.1 million in Q1 2026 per IFRX's latest filing, from $302937.7 in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.8 million in Q1 2022 and troughed at $302937.7 in Q4 2025.
- A 5-year average of $1.2 million and a median of $1.1 million in 2026 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2026: Share-based Compensation soared 95.98% in 2022, then plunged 57.76% in 2026.
- Over 5 years, Share-based Compensation stood at $472716.3 in 2022, then increased by 3.11% to $487398.6 in 2023, then slipped by 25.48% to $363215.6 in 2024, then slipped by 16.6% to $302937.7 in 2025, then soared by 263.7% to $1.1 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $302937.7, and $696615.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | - |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 687,392.90 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 302,937.67 |
| Dec 31, 2025 | 302,937.67 |
| Sep 30, 2025 | 696,615.38 |
| Sep 30, 2025 | 696,615.38 |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Mar 31, 2025 | 2.61 Mn |
| Dec 31, 2024 | 363,215.58 |
| Dec 31, 2024 | 363,215.58 |
| Sep 30, 2024 | 716,142.35 |
| Sep 30, 2024 | 716,142.35 |
| Jun 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 487,398.63 |
| Dec 31, 2023 | 487,398.63 |